# Samsung Medical Center

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/samsung-medical-center/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 53.6 |
| Citations | 4,420,543 |
| City | Seoul |
| Country | KR |
| Description | Samsung Medical Center is a research organisation in Seoul, KR. OpenAlex records 46,009 works and 4,420,543 citations for it. 11,136 researchers list it as their most recent affiliation. |
| Homepage | http://www.smc.or.kr |
| OpenAlex ID | https://openalex.org/I2802194831 |
| Region | Seoul |
| Researchers | 11,136 |
| ROR ID | https://ror.org/05a15z872 |
| Type | healthcare |
| Works | 46,009 |

## University collaborators

- [Sungkyunkwan University](https://scholariq.org/institutions/sungkyunkwan-university/)
- [University of California, Los Angeles](https://scholariq.org/institutions/university-of-california-los-angeles/)

## University papers

Showing 12 of 109.

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer](https://scholariq.org/papers/pembrolizumab-for-the-treatment-of-non-small-cell-lung-cancer/)
- [<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling](https://scholariq.org/papers/i-met-i-amplification-leads-to-gefitinib-resistance-in-lung-cancer-by-activating/)
- [Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer](https://scholariq.org/papers/crizotinib-versus-chemotherapy-in-advanced-i-alk-i-positive-lung-cancer/)
- [Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial](https://scholariq.org/papers/pembrolizumab-versus-chemotherapy-for-previously-untreated-pd-l1-expressing/)
- [Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer](https://scholariq.org/papers/osimertinib-or-platinum-pemetrexed-in-i-egfr-i-t790m-positive-lung-cancer/)
- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/alectinib-versus-crizotinib-in-untreated-i-alk-i-positive-non-small-cell-lung/)
- [AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer](https://scholariq.org/papers/azd9291-in-egfr-inhibitor-resistant-non-small-cell-lung-cancer/)
- [Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study](https://scholariq.org/papers/pembrolizumab-versus-methotrexate-docetaxel-or-cetuximab-for-recurrent-or/)
- [Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-after-sorafenib-in-patients-with-advanced-hepatocellular-carcinoma/)

## University researchers

- [Myung‐Ju Ahn](https://scholariq.org/researchers/myung-ju-ahn/)
- [Jin Seok Ahn](https://scholariq.org/researchers/jin-seok-ahn/)
- [Jong‐Mu Sun](https://scholariq.org/researchers/jong-mu-sun/)
- [Tae‐Young Chung](https://scholariq.org/researchers/tae-young-chung/)
- [Honsoul Kim](https://scholariq.org/researchers/honsoul-kim/)
- [Jeehun Lee](https://scholariq.org/researchers/jeehun-lee/)
- [Geonyoub Na](https://scholariq.org/researchers/geonyoub-na/)
- [Jiwon Lee](https://scholariq.org/researchers/jiwon-lee-2/)
- [Eun Yeon Joo](https://scholariq.org/researchers/eun-yeon-joo/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.